NGEN Insider Trading
NervGen Pharma Corp. Common stock (NGEN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $134.0M, listed on NASDAQ, employing roughly 8 people, carrying a beta of 0.73 to the broader market. NervGen Pharma Corp. Led by Adam H. Rogers, public since 2021-02-08.
No insider filings are on record under NGEN's own SEC company ID (CIK 1751912).
Filings Under Another SEC Company ID
107 filing lines on file were filed under an SEC company ID (CIK) other than NGEN's (1751912). Such a filing can be a predecessor company's (one that reorganized, redomiciled or converted files under a new CIK), a former holder of the NGEN ticker's, or another company's that NGEN or its insiders report holding; the CIK alone does not say which. They are not counted in the figures above.
| CIK | Lines | Dates | Securities |
|---|---|---|---|
| 1030339 | 107 | Aug 8, 1988 to Jun 25, 2008 | Common Stock, Performance Stock Option, Performance Option |
NGEN Institutional Ownership (13F)
As of Jun 30, 2026 (Q2 2026), 62 institutions reported holding 11,993,602 NGEN shares, valued at $24.9M as reported, 16.6% of its market cap (market cap of Jun 26, 2026). That is +17 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 20 opened a position, 3 closed one, 20 added and 7 trimmed.
Top Holders, Q2 2026
| Manager | Shares | Value | Change |
|---|---|---|---|
| Empery Asset Management, LP | 4,000,000 | $8.2M | New |
| Rock Springs Capital Management LP | 1,208,231 | $2.5M | New |
| DAFNA Capital Management LLC | 1,050,000 | $2.2M | New |
| Ghisallo Capital Management LLC | 1,000,000 | $2.1M | New |
| ARMISTICE CAPITAL, LLC | 678,000 | $1.4M | New |
| LMR Partners LLP | 600,000 | $1.2M | New |
| MARSHALL WACE, LLP | 435,962 | $898.1K | +235,603 |
| UBS Group AG | 379,726 | $782.2K | +318,209 |
| Stonepine Capital Management, LLC | 271,678 | $559.7K | New |
| JANE STREET GROUP, LLC | 270,750 | $557.7K | New |
By Quarter
| Quarter | Institutions | Shares | Value |
|---|---|---|---|
| Q2 2026 | 62 | 11,993,602 | $24.9M |
| Q1 2026 | 45 | 1,693,343 | $6.4M |
| Q4 2025 | 1 | 10,000 | $56.0K |
| Q2 2024 | 0 | 0 | $0 |
From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.
ETFs Holding NGEN
| Fund | Weight of NGEN | Shares (as reported) | Value (as reported) | Source updated |
|---|---|---|---|---|
| GWX State Street SPDR S&P International Small Cap ETF | 0.01% | 61,300 | $107.6K | Oct 8, 2026 |
| IBRN iShares Neuroscience and Healthcare ETF | 0.23% | 8,257 | $14.4K | Oct 8, 2026 |
From each fund's latest holdings file on record that shows NGEN's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as NGEN's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for NGEN reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is NGEN's share of that fund.
Learn how insider trading is reported and how to read the data →